Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

891
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
891
Cancer Vaccines01:30

Cancer Vaccines

488
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Science Journals.

Science (New York, N.Y.)Β·2026
Same author

Treating depression through G proteins.

Science signalingΒ·2026
Same author

Sense and stromal density.

Science signalingΒ·2026
Same author

In Science Journals.

Science (New York, N.Y.)Β·2026
Same author

In Science Journals.

Science (New York, N.Y.)Β·2026
Same author

Neuron-tumor synapses drive PDAC.

Science signalingΒ·2026
Same journal

ZNRF3 and RNF43 are active monomeric E3 ubiquitin ligases that self-associate.

Science signalingΒ·2026
Same journal

Allosteric ligands with distinct properties uncover tissue-specific physiological regulation mediated by free fatty acid receptor 2.

Science signalingΒ·2026
Same journal

Diacylglycerol kinase ΞΆ in B lymphocytes supports CD40-mediated immune synapse formation, mTORC1 signaling, and plasma cell fate.

Science signalingΒ·2026
Same journal

The APC/C adaptor Cdh1 stabilizes STING to potentiate innate immune activation in renal cell carcinoma.

Science signalingΒ·2026
Same journal

Fattening mother's milk with oxytocin.

Science signalingΒ·2026
Same journal

Virion display reveals MD-1 as an endogenous agonist for the orphan receptor GPRC5B.

Science signalingΒ·2026
See all related articles

Related Experiment Video

Updated: Aug 23, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Complement-ary immunity to lung cancer.

Leslie K Ferrarelli1

  • 1Science Signaling, AAAS, Washington, DC 20005, USA.

Science Signaling
|November 1, 2022
PubMed
Summary
This summary is machine-generated.

Restoring complement signaling in lung cancer improves immunotherapy effectiveness. This study demonstrates how targeting complement pathways can boost anti-cancer treatments in preclinical models.

More Related Videos

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

13.8K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

527

Related Experiment Videos

Last Updated: Aug 23, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
09:02

Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment

Published on: June 28, 2018

13.8K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

527

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • The complement system is a crucial part of innate immunity.
  • Dysregulation of complement signaling is implicated in various cancers, including lung cancer.
  • Current immunotherapies for lung cancer have limitations in efficacy for some patients.

Purpose of the Study:

  • To investigate the role of complement signaling in the tumor microenvironment of lung cancer.
  • To determine if restoring complement signaling can enhance the efficacy of immunotherapy in lung cancer mouse models.

Main Methods:

  • Utilized genetically engineered mouse models of lung cancer.
  • Administered immunotherapy agents in combination with strategies to restore complement signaling.
  • Assessed tumor growth, immune cell infiltration, and complement pathway activation.

Main Results:

  • Restoring complement signaling significantly enhanced the anti-tumor effects of immunotherapy.
  • Increased infiltration of cytotoxic T lymphocytes into tumors was observed.
  • Specific complement components were found to be critical for mediating the enhanced response.

Conclusions:

  • Targeting and restoring complement signaling represents a promising strategy to overcome resistance to immunotherapy in lung cancer.
  • This approach may improve clinical outcomes for patients with lung cancer receiving immunotherapy.